(MENAFN- GlobeNewsWire - Nasdaq) Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Feb. 06, 2025 (GLOBE ...

Revolutionizing CGM Accessibility and Performance Trinity Biotech's redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The device's ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Revolutionizing CGM Accessibility and Performance Trinity Biotech’s redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The device’s ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...

Shares of Trinity Biotech (NASDAQ:TRIB ... pivotal clinical trial for its next-gen continuous glucose monitoring (CGM) system. Based on data from 30 diabetic patients, Trinity (NASDAQ:TRIB ...

We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly," said John Gillard, CEO of Trinity Biotech. "The two largest CGM manufacturers ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. “The two largest CGM ...

John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...